(Q38284501)

1 September 2017

1 reference

title

An assessment of enterotoxigenic Escherichia coli and Shigella vaccine candidates for infants and children (English)

1 reference

enterotoxigenic Escherichia coli

1 September 2017

0 references

1 reference

Richard I Walker

1

1 reference

PubMed ID

25482842

1 September 2017

language of work or name

English

0 references

publication date

5 December 2014

1 reference

1 September 2017

1 reference

1 September 2017

33

1 reference

1 September 2017

8

1 reference

1 September 2017

954-965

1 reference

Etiology of diarrhea in older children, adolescents and adults: a systematic review

1 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Diarrhoea morbidity and mortality in older children, adolescents, and adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Global, regional, and national causes of child mortality in 2008: a systematic analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Early childhood diarrhea is associated with diminished cognitive function 4 to 7 years later in children in a northeast Brazilian shantytown

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Magnitude and impact of diarrheal diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Updating the DALYs for diarrhoeal disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Malnutrition as an enteric infectious disease with long-term effects on child development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Comorbidity in childhood in northern Ghana: magnitude, associated factors, and impact on mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Enterotoxigenic Escherichia coli virulence factors and vaccine approaches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

A combination vaccine consisting of three live attenuated enterotoxigenic Escherichia coli strains expressing a range of colonization factors and heat-labile toxin subunit B is well tolerated and immunogenic in a placebo-controlled double-blind phas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Expression of enterotoxigenic Escherichia coli colonization factors in Vibrio cholerae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic E. coli (ETEC) disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Immune responses elicited against multiple enterotoxigenic Escherichia coli fimbriae and mutant LT expressed in attenuated Shigella vaccine strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Progress and pitfalls in Shigella vaccine research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Live attenuated Shigella dysenteriae type 1 vaccine strains overexpressing shiga toxin B subunit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Construction and characterization of bivalent Shigella flexneri 2a vaccine strains SC608(pCFAI) and SC608(pCFAI/LTB) that express antigens from enterotoxigenic Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. Coli diarrhoea of travellers to Guatemala and Mexico.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Clinical trial to evaluate safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli prototype vaccine containing CFA/I overexpressing bacteria and recombinantly produced LTB/CTB hybrid protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Modern vaccines. Enteric infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Progress and hurdles in the development of vaccines against enterotoxigenic Escherichia coli in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Characterization of immunological cross-reactivity between enterotoxigenic Escherichia coli heat-stable toxin and human guanylin and uroguanylin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Evolutionary and functional relationships of colonization factor antigen i and other class 5 adhesive fimbriae of enterotoxigenic Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Novel antigens for enterotoxigenic Escherichia coli vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Shigella enterotoxin 1: an enterotoxin of Shigella flexneri 2a active in rabbit small intestine in vivo and in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Shigella enterotoxin-2 is a type III effector that participates in Shigella-induced interleukin 8 secretion by epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Molecular pathogenesis of Shigella spp.: controlling host cell signaling, invasion, and death by type III secretion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Recent progress towards development of a Shigella vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Identification of icsA, a plasmid locus of Shigella flexneri that governs bacterial intra- and intercellular spread through interaction with F-actin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Live-attenuated Shigella vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Two msbB genes encoding maximal acylation of lipid A are required for invasive Shigella flexneri to mediate inflammatory rupture and destruction of the intestinal epithelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Virulence, inflammatory potential, and adaptive immunity induced by Shigella flexneri msbB mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Isolation and Characterization of Gal E Mutant Ty 21a of Salmonella typhi: A Candidate Strain for a Live, Oral Typhoid Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Genome Sequence of Salmonella enterica Serovar Typhi Oral Vaccine Strain Ty21a

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Stable expression of Shigella sonnei form I O-polysaccharide genes recombineered into the chromosome of live Salmonella oral vaccine vector Ty21a

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Vaccine potential for inactivated shigellae.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Preparation of synthetic glycoconjugates as potential vaccines against Shigella flexneri serotype 2a disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Characterization of functional oligosaccharide mimics of the Shigella flexneri serotype 2a O-antigen: implications for the development of a chemically defined glycoconjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Substrate specificity of bacterial oligosaccharyltransferase suggests a common transfer mechanism for the bacterial and eukaryotic systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Production of glycoprotein vaccines in Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Inactivated and subunit vaccines to prevent shigellosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Mucosal adjuvanticity of a Shigella invasin complex with dna-based vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

High yield production process for Shigella outer membrane particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Age-Specific Prevalence of Serum Antibodies to the Invasion Plasmid and Lipopolysaccharide Antigens of Shigella Species in Chilean and North American Populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Broadly protective Shigella vaccine based on type III secretion apparatus proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Mucosal immunization with Shigella flexneri outer membrane vesicles induced protection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Nanoparticle-based vaccine for mucosal protection against Shigella flexneri in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Outer membrane protein A (OmpA) of Shigella flexneri 2a, induces protective immune response in a mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Purification and characterization of an immunogenic outer membrane protein of Shigella flexneri 2a

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Outer membrane protein A (OmpA) from Shigella flexneri 2a: a promising subunit vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Identification of a Campylobacter jejuni protein that cross-reacts with cholera toxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Oral immunization with cholera toxin provides protection against Campylobacter jejuni in an adult mouse intestinal colonization model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Recombinant PorA, the major outer membrane protein of Campylobacter jejuni, provides heterologous protection in an adult mouse intestinal colonization model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Vaccination with Dukoral against travelers' diarrhea (ETEC) and cholera

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Re-utilization of germinal centers in multiple Peyer's patches results in highly synchronized, oligoclonal, and affinity-matured gut IgA responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Five-year immunologic memory in Swedish volunteers after oral cholera vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Immunological memory after immunization with oral cholera B subunit--whole-cell vaccine in Swedish volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Sublingual immunization induces broad-based systemic and mucosal immune responses in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

7 January 2021

Sublingual vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Construction of a potential bivalent vaccine strain: introduction of Shigella sonnei form I antigen genes into the galE Salmonella typhi Ty21a typhoid vaccine strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

Induction of a local anti-IpaC antibody response in mice by use of a Shigella flexneri 2a vaccine candidate: implications for use of IpaC as a protein carrier

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

inferred from DOI database lookup

7 January 2021

based on heuristic

Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

inferred from DOI database lookup

7 January 2021

based on heuristic

Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.049

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2014.11.049

1 reference

1 September 2017

1 reference

PubMed ID

25482842